These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28116088)

  • 1. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
    Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
    J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
    Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
    Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.
    Trevor KT; Hersh EM; Brailey J; Balloul JM; Acres B
    Cancer Immunol Immunother; 2001 Oct; 50(8):397-407. PubMed ID: 11726134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
    Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
    Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
    Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
    Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
    Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
    Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
    Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
    Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
    Schaedler E; Remy-Ziller C; Hortelano J; Kehrer N; Claudepierre MC; Gatard T; Jakobs C; Préville X; Carpentier AF; Rittner K
    Vaccine; 2017 Jan; 35(4):577-585. PubMed ID: 28012777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
    Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
    Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines.
    Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP
    J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
    Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
    Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma.
    Hillman GG; Xu M; Wang Y; Wright JL; Lu X; Kallinteris NL; Tekyi-Mensah S; Thompson TC; Mitchell MS; Forman JD
    Hum Gene Ther; 2003 May; 14(8):763-75. PubMed ID: 12804139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.